These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 11588992)

  • 21. [Effective pain therapy with good tolerability. New opioid administration form by transdermal patch].
    MMW Fortschr Med; 2005 Nov; 147(46):66-7. PubMed ID: 16358643
    [No Abstract]   [Full Text] [Related]  

  • 22. Benefit-risk assessment of transdermal fentanyl for the treatment of chronic pain.
    Kornick CA; Santiago-Palma J; Moryl N; Payne R; Obbens EA
    Drug Saf; 2003; 26(13):951-73. PubMed ID: 14583070
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Three-cycle fentanyl patch system contributes to stable control of plasma fentanyl concentration in gynecologic cancer pain patients.
    Kanamori C; Kanamori T; Tanaka Y; Kanzaki H
    Taiwan J Obstet Gynecol; 2011 Mar; 50(1):79-84. PubMed ID: 21482380
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A feasibility study of transdermal buprenorphine versus transdermal fentanyl in the long-term management of persistent non-cancer pain.
    Mitra F; Chowdhury S; Shelley M; Williams G
    Pain Med; 2013 Jan; 14(1):75-83. PubMed ID: 23320402
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The use of transdermal fentanyl in pediatric oncology palliative care.
    Noyes M; Irving H
    Am J Hosp Palliat Care; 2001; 18(6):411-6. PubMed ID: 11712724
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A new once-a-day fentanyl citrate patch (Fentos Tape) could be a new treatment option in patients with end-of-dose failure using a 72-h transdermal fentanyl matrix patch.
    Koike K; Terui T; Nagasako T; Horiuchi I; Machino T; Kusakabe T; Hirayama Y; Mihara H; Yamakage M; Kato J; Nishisato T; Ishitani K
    Support Care Cancer; 2016 Mar; 24(3):1053-9. PubMed ID: 26248654
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Transdermal fentanyl in treating severe painful mucositis caused by autologous hematopoietic stem cell transplantation].
    Huang HQ; Cai QQ; Lin XB; Wang BF; Bu Q; Gao Y; Peng YL
    Ai Zheng; 2007 Apr; 26(4):390-3. PubMed ID: 17430658
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Transdermal fentanyl in the management of children with chronic severe pain: results from an international study.
    Finkel JC; Finley A; Greco C; Weisman SJ; Zeltzer L
    Cancer; 2005 Dec; 104(12):2847-57. PubMed ID: 16284992
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The efficacy of low-dose transdermal fentanyl in opioid-naïve cancer patients with moderate-to-severe pain.
    Kang JH; Oh SY; Song SY; Lee HY; Kim JH; Lee KE; Lee HR; Hwang IG; Park SH; Kim WS; Park YS; Park K
    Korean J Intern Med; 2015 Jan; 30(1):88-95. PubMed ID: 25589840
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical experience with transdermal and orally administered opioids in palliative care patients--a retrospective study.
    Clemens KE; Klaschik E
    Jpn J Clin Oncol; 2007 Apr; 37(4):302-9. PubMed ID: 17519302
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and safety of transdermal fentanyl and sustained-release oral morphine in patients with cancer and chronic non-cancer pain.
    Clark AJ; Ahmedzai SH; Allan LG; Camacho F; Horbay GL; Richarz U; Simpson K
    Curr Med Res Opin; 2004 Sep; 20(9):1419-28. PubMed ID: 15383190
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Treatment of chronic pain--use of transdermal fentanyl (Durogesic TTS)].
    Babić-Naglić D; Jajić Z; Gnjidić Z; Stambuk B
    Reumatizam; 2002; 49(2):33-7. PubMed ID: 12476759
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Re: The fentanyl transdermal patch in the dying phase.
    Kirkham SR
    J Pain Symptom Manage; 2003 Jul; 26(1):589-90; author reply 590. PubMed ID: 12850638
    [No Abstract]   [Full Text] [Related]  

  • 34. Impact of transdermal fentanyl on quality of life in rheumatoid arthritis.
    Berliner MN; Giesecke T; Bornhövd KD
    Clin J Pain; 2007; 23(6):530-4. PubMed ID: 17575494
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Factors influencing quality of life in cancer patients: the role of transdermal fentanyl in the management of pain.
    Payne R
    Semin Oncol; 1998 Jun; 25(3 Suppl 7):47-53. PubMed ID: 9671331
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Applying partially occluded fentanyl transdermal patches to manage pain in pediatric patients.
    Mitchell A; Smith HS
    J Opioid Manag; 2010; 6(4):290-4. PubMed ID: 20862908
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The role of transdermal fentanyl patches in the effective management of cancer pain.
    Gibbs M
    Int J Palliat Nurs; 2009 Jul; 15(7):354-9. PubMed ID: 19648851
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Low doses of transdermal fentanyl in opioid-naive patients with cancer pain.
    Mercadante S; Porzio G; Ferrera P; Aielli F; Adile C; Ficorella C
    Curr Med Res Opin; 2010 Dec; 26(12):2765-8. PubMed ID: 21034376
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Transdermal fentanyl in cachectic cancer patients.
    Heiskanen T; Mätzke S; Haakana S; Gergov M; Vuori E; Kalso E
    Pain; 2009 Jul; 144(1-2):218-22. PubMed ID: 19442446
    [TBL] [Abstract][Full Text] [Related]  

  • 40. From codeine to transdermal fentanyl for cancer pain control: a safety and efficacy clinical trial.
    Mystakidou K; Befon S; Kouskouni E; Gerolymatos K; Georgaki S; Tsilika E; Vlahos L
    Anticancer Res; 2001; 21(3C):2225-30. PubMed ID: 11501851
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.